哌罗匹隆与喹硫平治疗首发精神分裂症的临床研究  

The study of perospirone in the treatment of patients with schizophrenia

作　　者：马元业 周东林[1] 张子明[1] 李捷[1] 

机构地区：[1]甘肃省天水市第三人民医院,741000

出　　处：《四川精神卫生》2012年第1期32-34,共3页Sichuan Mental Health

摘　　要：目的比较哌罗匹隆与喹硫平治疗首发精神分裂症的疗效及安全性。方法将64例首发精神分裂症患者随机分为哌罗匹隆组(研究组)32例,喹硫平组(对照组)32例,分别给予哌罗匹隆和喹硫平治疗,疗程6周。采用阳性与阴性症状量表(PANSS)评定疗效,治疗时出现的症状量表(TESS)评定不良反应。结果治疗6周后两组PANSS评分较治疗前均有显著下降。哌罗匹隆组显效率为65.6%,有效率为78.1%;喹硫平组显效率为62.5%,有效率为75%,两组间疗效差异无统计学意义(P>0.05),两组间TESS评分差异亦无统计学意义。结论哌罗匹隆治疗首发精神分裂症的疗效及安全性与喹硫平相当。Objective To compare the efficacy and safety of perospirone in treatment of schizophrenia.Methods 64 patients of schizophrenia were randomly assigned to perospirone group（32 cases） and quetiapine group（32 cases） for 6 weeks.The efficacy were asseessed by positive symptom and negative symptom scale（PANSS）,adverse side effect were evaluated with treatment emergent symptom scale（TESS）.Results By the end of the treatment,the scores of PANSS in both groups decreased significantly compared to the baseline.The significant rate in the two groups was 65.6% and 62.5%.And the effective rate was 78.1% and 75.0%.No significant difference was found in effect between the two groups（P0.05）.Conclusion Perospirone has similar efficacy and safety to quetiapine in tretment of schizophrenia.

关 键 词：哌罗匹隆 喹硫平 首发精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]